120 related articles for article (PubMed ID: 30188237)
1. Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
Rubenstein JL
Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237
[No Abstract] [Full Text] [Related]
2. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy.
Sabio E; Chan TA
Genome Med; 2019 Jul; 11(1):43. PubMed ID: 31340855
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironment controls the outcome of PD-1 blockade in cutaneous immune response.
Ogawa T; Ishitsuka Y; Saito A; Nakamura Y; Watanabe R; Okiyama N; Fujisawa Y; Fujimoto M
Allergy; 2019 Nov; 74(11):2257-2261. PubMed ID: 31063597
[No Abstract] [Full Text] [Related]
4. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
6. 20 years of rituximab treatment: what have we learnt?
Renner C
Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
[No Abstract] [Full Text] [Related]
7. CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils.
Zheng X; Zhang N; Qian L; Wang X; Fan P; Kuai J; Lin S; Liu C; Jiang W; Qin S; Chen H; Huang Y
Int J Cancer; 2020 Mar; 146(6):1730-1740. PubMed ID: 31840816
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Ren Z; Guo J; Liao J; Luan Y; Liu Z; Sun Z; Liu X; Liang Y; Peng H; Fu YX
Clin Cancer Res; 2017 Jan; 23(1):193-203. PubMed ID: 27354469
[TBL] [Abstract][Full Text] [Related]
9. Chemokines and cancer: new immune checkpoints for cancer therapy.
Karin N
Curr Opin Immunol; 2018 Apr; 51():140-145. PubMed ID: 29579623
[TBL] [Abstract][Full Text] [Related]
10. Trafficking of lymphocytes into the CNS.
Schwab N; Schneider-Hohendorf T; Wiendl H
Oncotarget; 2015 Jul; 6(20):17863-4. PubMed ID: 26255669
[No Abstract] [Full Text] [Related]
11. Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis.
Jiang S; Zhen H; Jiang H
J Adolesc Young Adult Oncol; 2019 Oct; 8(5):623-627. PubMed ID: 31150309
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS
Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Cencini E; Fabbri A; Bocchia M
Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
[No Abstract] [Full Text] [Related]
14. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
15. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma.
Di Lullo G; Marcatti M; Heltai S; Tresoldi C; Paganoni AM; Bordignon C; Ciceri F; Protti MP
Front Immunol; 2018; 9():3171. PubMed ID: 30719025
[TBL] [Abstract][Full Text] [Related]
17. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
[TBL] [Abstract][Full Text] [Related]
18. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
19. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide.
Garnier A; Delbos F; Guillaume T; Peterlin P; Le Bourgeois A; Béné MC; Le Bris Y; Malard S; Duquesne A; Gauvrit I; Moreau P; Cesbron A; Chevallier P
Bone Marrow Transplant; 2018 Aug; 53(8):1044-1047. PubMed ID: 29391525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
